Abstract:Introduction: Candida species are endowed with the ability to produce biofilms, which is one of the causes of pathogenicity, as biofilms protect yeasts from antifungal drugs. Candida glabrata ( Nakaseomyces glabrata ) is one of the most prevalent pathogenic yeasts in humans and a biofilm producer. Methods: The study was aimed at evaluating the combined effects of two highly promising antifungal biomolecules (AF 4 and AF 5 ) lipopeptide in nature, chromatographically purified to homogeneity from Bacillus subtilis ( B. subtilis ) and the standard antifungal fluconazole (at different concentrations) to demonstrate C. glabrata biofilm formation inhibition. Biofilm production and inhibition were evaluated by quantification of the biofilm biomass and metabolic activity using crystal violet (CV) staining and XTT reduction assays, respectively. Microscopic techniques such as confocal scanning laser microscopy (CSLM) and scanning electron microscopy (SEM) were employed to visualize biofilm formation and inhibition. Results and Discussion: Compared to untreated and fluconazole-treated biofilms, an enhanced in vitro anti-biofilm effect of the antifungal lipopeptides AF 4 /AF 5 alone and their combinations with fluconazole was established. The lipopeptides AF 4 /AF 5 alone at 8 and 16 μg/mL exhibited significant biomass and metabolic activity reductions. SEM and CSLM images provided evidence that the lipopeptide exposure results in architectural alterations and a significant reduction of C. glabrata biofilms, whereas (2′, 7′-dichlorofluorescin diacetate (DCFDA) and propidium iodide (PI) analyses showed reactive oxygen species (ROS) generation along with membrane permeabilization. The estimation of exopolysaccharides (EPS) in AF 4 /AF 5 -treated biofilms indicated EPS reduction. The combinations of fluconazole (64/128 μg/mL) and AF 4 /AF 5 lipopeptide (16 μg/mL) were found to significantly disrupt the mature (24 h) biofilms as revealed by CSLM and SEM studies. The CSLM images of biofilms were validated using COMSTAT. The FTIR-analyses indicate the antibiofilm effects of both lipopeptides on 24 h biofilms to support CSLM and SEM observations. The combinations of fluconazole (64/128 μg/mL) and AF 4 /AF 5 lipopeptide were found to disrupt the mature biofilms; the study also showed that the lipopeptides alone have the potentials to combat C. glabrata biofilms. Taken together, it may be suggested that these lipopeptide leads can be optimized to potentially apply on various surfaces to either reduce or nearly eradicate yeast biofilms.

In Vitro Activity of Verapamil Alone and in Combination with Fluconazole or Tunicamycin Against Candida Albicans Biofilms.

Inhibitory effect of verapamil on Candida albicans hyphal development, adhesion and gastrointestinal colonization.

Synergistic Effect of Doxycycline and Fluconazole Against Candida Albicans Biofilms and the Impact of Calcium Channel Blockers.

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans

The Calcium Channel Blocker Verapamil Inhibits Oxidative Stress Response in Candida albicans

Verapamil Enhances the Activity of Caspofungin against Cryptococcus neoformans Coincides with Inhibited Ca2+ /CN Pathway and Damage with Cell Wall Integrity

The Effect of Fluconazole in Combination with Rifampin in Vitro on Candida Albicans Biofilms

In Vitro and in Vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus Fumigatus

In Vitro and in Vivo Effects of the Combination of Myricetin and Miconazole Nitrate Incorporated to Thermosensitive Hydrogels, on C. Albicans Biofilms

The Combination of Minocycline and Fluconazole Causes Synergistic Growth Inhibition Against Candida Albicans: an in Vitro Interaction of Antifungal and Antibacterial Agents.

The Research about Candida Albicans Biofilms Eliminated by Miconazole Combined with Drug Efflux Pump Inhibitors

Anti-Biofilm Activity of Cocultimycin A against Candida albicans

In vitro and in vivo analysis of monotherapy and dual therapy with ethyl caffeate and fluconazole on virulence factors of Candida albicans and systemic candidiasis

Two promising Bacillus-derived antifungal lipopeptide leads AF4 and AF5 and their combined effect with fluconazole on the in vitro Candida glabrata biofilms

In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and Staphylococcus aureus

In Vitro Interactions Between Tacrolimus and Azoles Against Candida Albicans Determined by Different Methods.

The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms

In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures.

Antifungal Activity, Synergism with Fluconazole or Amphotericin B and Potential Mechanism of Direct Current against Candida albicans Biofilms and Persisters

Alizarin and Chrysazin Inhibit Biofilm and Hyphal Formation by Candida albicans